{
  "docId": "019de071-473e-712d-87f0-b99471a2308d",
  "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea",
  "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7827299,
  "pageNumber": 39,
  "pageCount": 40,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide features a 3D molecular structure visualization, likely a protein-ligand complex.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/39",
  "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d",
  "deckJsonHref": "/decks/019de071-473e-712d-87f0-b99471a2308d.json",
  "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.65,
        "y": 0.15
      },
      "kind": "image",
      "text": "3D molecular structure",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66582587-97ab-4e70-a61e-a167a97cfae8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.07,
        "y": 0.42
      },
      "kind": "list",
      "text": "Innovative molecular structures with the potential to overcome the dual challenges of kinase resistance and selectivity in the CNS and in the periphery; Potential for differentiated inhibition of proven kinase targets with opportunities for clinical utility earlier in the treatment paradigm",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae9278df-a7cc-4880-a762-3d1284d5a9d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "Parallel lead programs in ROS1-positive and ALK-positive NSCLC: Multiple opportunities for proof-of-concept clinical data",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3774444b-d1d3-48a7-acd4-b67096c86af1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.07,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Robust development pipeline leveraging established approach: Two additional drug candidates expected to be nominated in 2022",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b371ea36-ec1e-4ebb-a392-59f48bc72c13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.32
      },
      "kind": "title",
      "text": "PRECISELY Targeted Therapies for patients with cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "839ee10c-b266-4fd0-88da-a012a395062e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}